Clinical prognostic factors in patients with recurrent or metastatic carcinoma of the head and neck treated with immune checkpoints therapies.

Published on May 26, 2019in Journal of Clinical Oncology32.956
· DOI :10.1200/JCO.2019.37.15_SUPPL.E17530
Carlo Resteghini13
Estimated H-index: 13
,
Stefano Cavalieri8
Estimated H-index: 8
+ 11 AuthorsLisa Licitra67
Estimated H-index: 67
(University of Milan)
Source
Abstract
e17530Background: Immunotherapy (IT) provides advantages in a small proportion of recurrent / metastatic head and neck squamous cell carcinoma (RM HNSCC) patients (pts). Predictive biomarkers are s...
References0
Newest
Cited By3
Newest
#1Maria Tsikala-Vafea (Brown University)H-Index: 1
#2Neel Belani (Brown University)
Last. Dimitrios Farmakiotis (Brown University)H-Index: 26
view all 5 authors...
OBJECTIVES Observational and experimental studies suggest that antibiotic use close to administration of immune checkpoint inhibitors (ICI) can negatively affect tumor response and patient survival, due to microbiome dysbiosis and the resultant suppression of host immune response against neoplastic cells. METHODS We conducted a systematic search of PUBMED and EMBASE for studies published between 1/1/17 and 6/1/20, evaluating the association between antibiotic use and clinical outcomes in cancer ...
Source
#1Yang Yu (Lanzhou University)H-Index: 3
#1Yang Yu (Lanzhou University)H-Index: 1
Last. Hao Chen (Lanzhou University)H-Index: 13
view all 9 authors...
Antibiotic (ATB) use seems to negatively affect the outcomes of immune checkpoint inhibitors (ICIs). The aim of this review is to clarify whether ATB use influences the efficacy of ICI treatment in cancer patients. Databases of MEDLINE, Embase, and Cochrane Library were searched for reports published in English between January 2007 and December 2019. We included studies that compared the outcomes of ATB use and no-ATB use in cancer patients using ICIs. Two reviewers independently selected eligib...
Source
#1Andrea Botticelli (Sapienza University of Rome)H-Index: 18
#2Silvia Mezi (Sapienza University of Rome)H-Index: 13
Last. Paolo Marchetti (Sapienza University of Rome)H-Index: 51
view all 14 authors...
Abstract The immune checkpoint inhibitors, a class of drugs able to block immune suppressive pathways in order to prime an anticancer immunity, revolutionized standard of care in platinum-refractory recurrent and/or metastatic head and neck carcinoma (R/M HNSCC). The PD-1/ PD-L1 axis is involved in the genesis, maintenance and progression of HNSCC and represents the target of checkpoint inhibitors. HNSCC is an immunosuppressive disease with a high inflammatory component in tumor microenvironment...
4 CitationsSource